Publication: Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study
Loading...
Files
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background Patients with non-alcoholic fatty liver disease (NAFLD) and more advanced fibrosis tend to have more impairment in their health-related quality of life and other patient-reported outcomes (PROs). Aim To assess the association of PROs with select non-invasive tests (NITs) for fibrosis including FAST, Agile 3+ and Agile 4 scores Methods We enrolled patients with an established diagnosis of NAFLD who were seen in a tertiary care clinic into the NAFLD/NASH Registry. The FAST, Agile 3+ and Agile 4 scores were calculated using liver stiffness measurements by transient elastography and laboratory parameters. PROs were assessed using FACIT-F, CLDQ-NASH and WPAI instruments (total of 17 domain and summary scores). Results There were 1509 patients with NAFLD (mean age: 49 +/- 11 years, 50% men, 41% employed, 30% advanced fibrosis and 20% cirrhosis). The mean FAST, Agile 3+ and Agile 4 scores were 0.39 +/- 0.26, 0.35 +/- 0.31 and 0.12 +/- 0.23, respectively. Subjects with lower FAST, Agile 3+ and Agile 4 scores had the highest scores in select domains of FACIT-F, CLDQ-NASH and WPAI (p < 0.05 in comparison to subjects with elevated or high-risk NIT scores). Correlations with continuous NITs were significantly negative for Emotional and Functional well-being (FACIT-F), Activity/energy, Systemic symptoms, Worry and total scores (CLDQ-NASH), and Activity of WPAI (p < 0.05); the strongest was for Worry (CLDQ-NASH) with FAST (R = -0.17, p < 0.0001). The PRO scores of patients with NAFLD were lower than those of matched patients with chronic hepatitis B (p < 0.05 for 9/17 domain and summary scores). Conclusion Patients with NAFLD and high FAST, Agile 3+ or Agile 4 scores experience impairment of health-related quality of life.
Description
Keywords
Tıp, Temel Eczacılık Bilimleri, Dahili Tıp Bilimleri, İç Hastalıkları, Gastroenteroloji-(Hepatoloji), Eczacılık, Yaşam Bilimleri, Sağlık Bilimleri, Temel Bilimler, Medicine, Basic Pharmaceutics Sciences, Internal Medicine Sciences, Internal Diseases, Gastroenterology and Hepatology, Pharmacology and Therapeutics, Life Sciences, Health Sciences, Natural Sciences, GASTROENTEROLOJİ VE HEPATOLOJİ, Klinik Tıp, Klinik Tıp (MED), FARMAKOLOJİ VE ECZACILIK, Farmakoloji ve Toksikoloji, Yaşam Bilimleri (LIFE), GASTROENTEROLOGY & HEPATOLOGY, CLINICAL MEDICINE, Clinical Medicine (MED), PHARMACOLOGY & PHARMACY, PHARMACOLOGY & TOXICOLOGY, Life Sciences (LIFE), Farmakoloji, Farmakoloji, Toksikoloji ve Eczacılık (çeşitli), Genel Farmakoloji, Toksikoloji ve Eczacılık, Farmakoloji (tıbbi), Hepatoloji, Gastroenteroloji, İlaç Rehberleri, Pharmacy, Pharmacology, Pharmacology, Toxicology and Pharmaceutics (miscellaneous), General Pharmacology, Toxicology and Pharmaceutics, Pharmacology (medical), Hepatology, Gastroenterology, Drug Guides
Citation
YILMAZ Y., Toraman A. E. , Alp C., Dogan Z., Keklikkiran C., Stepanova M., Younossi Z., "Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022
